📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:35
0 analysed today
FollowTelegram
0
Today
150,433
All-time analysed
43,087
Positive
6,692
Negative
91,903
Neutral
8,683
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Genomic Valley Biotech Q1 FY27 Results: Net Profit at ₹0.015 Cr on Revenue of ₹0.038 Cr
Genomic Valley Biotech approved its standalone unaudited financial results for the quarter ended June 30, 2026. The company registered revenue of ₹0.038 crore, down from ₹0.09 crore in the corresponding quarter of the previous year. Net profit stood at ₹0.015 crore (EPS of ₹0.05), recovering from a net loss of ₹0.01 crore in the previous quarter (Q4 FY26). The statutory auditors issued an unmodified limited review report.
Confidence: HIGH
What changedFormal approval and release of standalone unaudited financial results for Q1 FY27.
Why it mattersDemonstrates ongoing minimal revenue scale and thin profitability for a microcap company with an ₹8 crore market capitalization.
Revenue (Jun 2026 Q): ₹0.038 crNet Profit (Jun 2026 Q): ₹0.0146 crQuarterly EPS: ₹0.05Board Meeting Date: 14th August 2026
📅 Short termSubdued trading reaction expected due to negligible absolute revenue figures and illiquid trading volume.
📈 Long termLimited structural significance unless the business demonstrates a clear pathway to scale commercial biotech revenues.
⚠ Risk flags
- Extremely small revenue base (annual revenue ₹0.27 Cr in FY26)
- Elevated valuation multiple (P/E ~580x) against marginal earnings
Key Highlights
Standalone quarterly revenue reported at ₹0.038 crore for the quarter ended June 30, 2026.
Net profit recorded at ₹0.0146 crore with an EPS of ₹0.05.
Board meeting concluded in 40 minutes (03:00 PM to 03:40 PM on August 14, 2026).
Statutory auditor ANDROS & CO issued a clean/unmodified Limited Review Report.
👀 What to Watch
Track subsequent quarterly filings to see if commercial operations scale beyond the current sub-₹0.1 crore quarterly run rate.
Genomic Valley Biotech Approves Q1 FY27 Un-audited Financial Results
Genomic Valley Biotech Ltd has approved its standalone un-audited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of only ‑8 Cr and has seen a significant decline in annual revenue from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26. Recent quarterly performance shows revenue stagnating between ‑0.04 Cr and ‑0.09 Cr. The board meeting was brief, lasting 40 minutes, and the statutory auditors provided a standard limited review report without qualifications.
Confidence: HIGH
What changedThe company has formally approved and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with negligible revenue, quarterly results are the only window into whether the business is maintaining its 'going concern' status or finding new revenue streams.
Market Capitalization: ‑8 CrFY26 Annual Revenue: ‑0.27 CrFY25 Annual Revenue: ‑0.84 CrTTM P/E Ratio: 414.4Promoter Holding: 46.06%
📅 Short termThe stock is likely to remain neutral given the extremely small scale of operations and lack of significant growth catalysts in the filing.
📈 Long termLimited structural significance unless the company can scale its biotechnology operations beyond the current sub-1 crore annual revenue level.
⚠ Risk flags
- Extremely low revenue scale
- High valuation (P/E 414.4) relative to earnings
- Micro-cap liquidity risk
Key Highlights
Board approved standalone un-audited financial results for the quarter ended June 30, 2026
Company revenue has declined significantly from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26
Market capitalization remains extremely low at ‑8 Cr with a high P/E ratio of 414.4
The board meeting commenced at 03:00 P.M. and concluded at 03:40 P.M. on August 14, 2026
Promoter holding has remained stable at 46.06% as of June 2026
👀 What to Watch
Investors should examine the full quarterly P&L to see if the company has managed to arrest the revenue decline seen over the last four quarters.
